Phase
Condition
Neuroendocrine Carcinoma
Small Cell Lung Cancer
Carcinoma
Treatment
Atezolizumab
Retifanlimab
Avelumab
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
Signed Informed Consent Form and willing to comply with all study procedures.
Participants with ES-SCLC (defined as Stage IV per NCCN guidelines Version 1.2024) or recurrent locally advanced or metastatic MCC (per NCCN guidelines Version 1.2024) documented by histology or cytology.
Participants eligible to receive immune checkpoint inhibitor (CPI) monotherapy at the start of treatment with 225Ac-SSO110 or patients already on CPI monotherapy for 7 weeks.
ECOG performance status of 0 or 1. Life expectancy of at least 6 months.
Positive 68Ga-SSO120 scan (Investigator-assessed) during screening.
Exclusion
Key Exclusion Criteria:
Participants with unstable spinal cord compression.
Any previous systemic radioligand therapy or extensive radiotherapy.
Participants receiving or planned to receive consolidative chest radiation.
History of primary immunodeficiency, transplantation or CAR-T cell therapy.
Major surgical procedure except diagnostic biopsy within 28 days prior to enrolment or scheduled to have major surgery during the study.
Inadequate organ or marrow function.
Study Design
Connect with a study center
Biogenix Molecular
Miami, Florida 33165
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.